IRONWOOD PHARMACEUTICALS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $296.2M | $351.4M | $442.7M | $410.6M | $413.8M |
| Selling, general & administrative | $82.3M | $144.3M | $158.3M | $116.0M | $111.1M |
| Research and development | $95.1M | $111.4M | $116.1M | $44.3M | $70.4M |
| Operating income | $98.5M | $93.1M | -$945.4M | $250.3M | $232.3M |
| Interest expense | $32.7M | $33.0M | $21.6M | $7.6M | $31.1M |
| Pretax income | $70.0M | $65.2M | -$948.1M | $252.4M | $200.7M |
| Income tax expense | $46.0M | $64.3M | $83.5M | $77.4M | -$327.8M |
| Net income | $24.0M | $880,000 | -$1.0B | $175.1M | $528.4M |
| Balance Sheet | |||||
| Cash and equivalents | $215.5M | $88.6M | $92.2M | $656.2M | $620.1M |
| Current assets | $274.2M | $182.4M | $233.3M | $780.6M | $745.2M |
| Total assets | $396.9M | $350.9M | $471.1M | $1.1B | $1.1B |
| Current liabilities | $242.2M | $38.8M | $276.1M | $25.5M | $161.7M |
| Total debt | — | — | — | $412.8M | $539.3M |
| Stockholders' equity | -$261.8M | -$301.3M | -$346.3M | $652.4M | $605.9M |
| Cash Flow Statement | |||||
| Cash from operations | $127.0M | $103.5M | $183.4M | $273.8M | $261.9M |
| Depreciation and amortization | $1.1M | $1.2M | $1.2M | $1.4M | $1.5M |
| Stock-based compensation | $17.2M | $29.9M | $32.0M | $27.0M | $22.3M |
| Capital expenditure | $34,000 | $142,000 | $273,000 | $136,000 | $265,000 |
| Free cash flow | $127.0M | $103.4M | $183.2M | $273.6M | $261.6M |
| Share repurchases | — | — | $123.4M | $126.4M | $24.1M |
Shares outstanding 164.6M · Free float 85.1%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.